Welcome to BCAL Diagnostics
An Advanced Way For Breast Cancer Detection
About BCAL Diagnostics
A Leading Biotechnology Company
BCAL Diagnostics is developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, accessible and cost effective. Breast cancer is the most common cancer amongst women, and improving the effectiveness of the screening and diagnosis technology used is a high priority.
The Company
Since forming in 2010, BCAL Diagnostics has been striving to address the issues surrounding the early detection and a more accurate method of screening for breast cancer
The BCAL Test
The current breast cancer screening (BCS) market is dominated by imaging technologies such as Mammograms and Ultrasound. BCS is one of the few screening tests with broad government funding
Contact Us
For more information on BCAL Diagnostics, its projects and investment opportunities please contact us
Our Mission
BCAL Diagnostics aims to shift the paradigm in breast cancer screening and diagnosis by introducing a blood test for detection and monitoring of the disease.
The implication of such a technology could revolutionise the way we prevent and manage breast cancer by allowing a blood sample to be taken remote from the site of analysis.
Our aim is to develop technology that would allow access to more women, anywhere in the world, who could provide a blood sample, at a time and place of their convenience. Such a test would fit into a woman's routine health regime and be incorporated into their personal lifestyle.
Past Events
Aus Biz TV Interview
BCAL Diagnostics has closed off a $4M pre-IPO capital raise to fund trials of its breast cancer blood test. Chairperson Jayne Shaw says it could revolutionise how we detect cancer cells.
Jan 2021
